<DOC>
	<DOCNO>NCT03017014</DOCNO>
	<brief_summary>The primary objective study evaluate long-term effectiveness adalimumab pediatric participant start treatment Crohn 's disease real life condition , namely describe time loss clinical benefit time event approach . Main secondary objective describe growth pubertal development describe long-term safety . The participant followed-up 10 year .</brief_summary>
	<brief_title>A Study Assess Safety Effectiveness Adalimumab Treating Children Adolescents With Crohn 's Disease Real Life Conditions</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>With confirm diagnosis Crohn 's disease Adalimumabnaïve patient ( patient receive antiTNF adalimumab may enter study ) Starting treatment adalimumab Guardian capable willing grant authorization use/disclosure data collect patient able comply requirement study protocol . Participants history treatment adalimumab Participants enrol concomitant interventional clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>Humira®</keyword>
	<keyword>Adalimumab</keyword>
</DOC>